FDA Adverse Event Injury Summary report: N

EDWARDS SAPIEN XT TRANSCATHETER HEART VLV (26MM)

MDR report key: 5217399 · Received November 11, 2015

Report

Report Number
2015691-2015-03042
Event Type
Injury
Date Received
November 11, 2015
Date of Event
March 9, 2015
Report Date
October 15, 2015
Manufacturer
EDWARDS LIFESCIENCES
Product Code
NPT
PMA / PMN Number
P130009
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
UK
Reporter Occupation
OTHER HEALTH CARE PROFESSIONAL

Narratives

Additional Manufacturer Narrative · 1

THE EDWARDS SAPIEN XT TRANSCATHETER HEART VALVE IS INDICATED FOR PATIENTS WITH SEVERE SYMPTOMATIC CALCIFIED NATIVE AORTIC VALVE STENOSIS. DEPLOYMENT OF THE SAPIEN XT VALVE IN A PREVIOUSLY IMPLANTED MITRAL SURGICAL VALVE IS NOT INDICATED PER THE LABELING; THEREFORE, THE LABELING (IFUS AND EW TRAINING MANUALS) DO NOT INSTRUCT THE OPERATOR HOW TO POSITION THE SAPIEN XT VALVE IN THIS SCENARIO. COMPLAINT HISTORIES FOR ALL REPORTED EVENTS ARE REVIEWED AGAINST TRENDING CONTROL LIMITS ON A MONTHLY BASIS, AND ANY EXCURSIONS ABOVE THE CONTROL LIMITS ARE ASSESSED AND DOCUMENTED AS PART OF THIS MONTHLY REVIEW. NO CORRECTIVE OR PREVENTATIVE ACTIONS ARE REQUIRED.

Description of Event or Problem · 1

AS PER THE ARTICLE "FACTORS INFLUENCING LEFT VENTRICULAR OUTFLOW TRACT OBSTRUCTION FOLLOWING A MITRAL VALVE-IN-VALVE OR VALVE-IN-RING PROCEDURE, PART 1", A 26MM SAPIEN XT VALVE WAS IMPLANTED WITHIN A MOSAIC MITRAL PROSTHESIS AND THE GRADIENT ACROSS THE LVOT WAS MEASURED TO BE 30MM. THE PATIENT WAS DISCHARGED ON 7 DAYS POST PROCEDURE, BUT PRESENTED WITHIN 6 WEEKS IN CCF. THE INVESTIGATIONS REVEALED AN INCREASE IN LVOT GRADIENT TO 60 MM. REDO OPEN SURGERY WAS UNDERTAKEN AND THE MITRAL SHV WAS REMOVED ALONG WITH THE SAPIEN XT VALVE. VISUALIZATION OF THE AORTA CONFIRMED SIGNIFICANT LVOT OBSTRUCTION.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
747294 EDWARDS SAPIEN XT TRANSCATHETER HEART VLV (26MM) AORTIC VALVE, PROSTHESIS, PERCUTANEOUSLY DELIVERED NPT EDWARDS LIFESCIENCES 9300TFX26

Patients

Seq Age Sex Outcome Treatment
1 60 YR Required Intervention